Evidence map›Paper›PMID 41621865›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors.

Shuichi Matsuoka, Hirokazu Tokuyasu, Katsunori Arai, Hiromitsu Sakai, Chika Esumi, Akira Yamasaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuichi MatsuokaRespiratory Medicine Division, Matsue Red Cross Hospital, Japan.
Hirokazu TokuyasuRespiratory Medicine Division, Matsue Red Cross Hospital, Japan.
Katsunori AraiRespiratory Medicine Division, Matsue Red Cross Hospital, Japan.
Hiromitsu SakaiRespiratory Medicine Division, Matsue Red Cross Hospital, Japan.
Chika EsumiPathology Division, Matsue Red Cross Hospital, Japan.
Akira YamasakiDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a case of successfully treated synchronous advanced cancers: programmed death-ligand1 (PD-L1)-negative squamous cell carcinoma of the left upper lung lobe and adenocarcinoma of the ascending colon. As lung cancer was prioritized as the primary therapeutic target, the patient received a combination of anti-PD-L1 and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies, along with chemotherapy (the POSEIDON regimen). This approach proved effective against both lung and colon cancer. Subsequent testing revealed high-frequency microsatellite instability (MSI-H) in the colon cancer. These findings highlight the therapeutic potential of combined anti-PD-L1 and anti-CTLA-4 antibodies in the treatment of PD-L1-negative lung and MSI-H colorectal cancers.

Indexed as

AdenocarcinomaCarcinoma, Squamous CellColonic NeoplasmsImmune Checkpoint InhibitorsLung NeoplasmsNeoplasms, Multiple PrimaryB7-H1 AntigenCTLA-4 AntigenHumansMicrosatellite InstabilityTreatment OutcomeB7-H1 AntigenCTLA-4 AntigenImmune Checkpoint Inhibitorscytotoxic T lymphocyte-associated protein-4high-frequency microsatellite instabilityimmune checkpoint inhibitorsprogrammed death 1synchronous multiple cancers

Identifiers

PMID41621865
PMCPMC13627645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.